343 related articles for article (PubMed ID: 35153298)
21. The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments.
Outh-Gauer S; Morini A; Tartour E; Lépine C; Jung AC; Badoual C
Head Neck Pathol; 2020 Jun; 14(2):330-340. PubMed ID: 32124416
[TBL] [Abstract][Full Text] [Related]
22. CD28/PD1 co-expression: dual impact on CD8
Palermo B; Franzese O; Frisullo G; D'Ambrosio L; Panetta M; Campo G; D'Andrea D; Sperduti I; De Nicola F; Goeman F; Gallina F; Visca P; Facciolo F; Nisticò P
J Exp Clin Cancer Res; 2023 Oct; 42(1):287. PubMed ID: 37898752
[TBL] [Abstract][Full Text] [Related]
23. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma.
Mei Z; Huang J; Qiao B; Lam AK
Int J Oral Sci; 2020 May; 12(1):16. PubMed ID: 32461587
[TBL] [Abstract][Full Text] [Related]
25. High HPK1
Zhang J; Ren Z; Hu Y; Shang S; Wang R; Ma J; Zhang Z; Wu M; Wang F; Yu J; Chen D
Int Immunopharmacol; 2024 Jan; 127():111363. PubMed ID: 38101218
[TBL] [Abstract][Full Text] [Related]
26. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
[TBL] [Abstract][Full Text] [Related]
27. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
28. Establishment and validation of exhausted CD8+ T cell feature as a prognostic model of HCC.
Shi J; Li G; Liu L; Yuan X; Wang Y; Gong M; Li C; Ge X; Lu S
Front Immunol; 2023; 14():1166052. PubMed ID: 37077914
[TBL] [Abstract][Full Text] [Related]
29. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Sato-Kaneko F; Yao S; Ahmadi A; Zhang SS; Hosoya T; Kaneda MM; Varner JA; Pu M; Messer KS; Guiducci C; Coffman RL; Kitaura K; Matsutani T; Suzuki R; Carson DA; Hayashi T; Cohen EE
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931759
[TBL] [Abstract][Full Text] [Related]
30. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
31. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
[TBL] [Abstract][Full Text] [Related]
32. Dynamic CD8
Rahim MK; Okholm TLH; Jones KB; McCarthy EE; Liu CC; Yee JL; Tamaki SJ; Marquez DM; Tenvooren I; Wai K; Cheung A; Davidson BR; Johri V; Samad B; O'Gorman WE; Krummel MF; van Zante A; Combes AJ; Angelo M; Fong L; Algazi AP; Ha P; Spitzer MH
Cell; 2023 Mar; 186(6):1127-1143.e18. PubMed ID: 36931243
[TBL] [Abstract][Full Text] [Related]
33. Spatial and Single-Cell Transcriptomics Reveal a Cancer-Associated Fibroblast Subset in HNSCC That Restricts Infiltration and Antitumor Activity of CD8+ T Cells.
Li C; Guo H; Zhai P; Yan M; Liu C; Wang X; Shi C; Li J; Tong T; Zhang Z; Ma H; Zhang J
Cancer Res; 2024 Jan; 84(2):258-275. PubMed ID: 37930937
[TBL] [Abstract][Full Text] [Related]
34. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
[TBL] [Abstract][Full Text] [Related]
36. Immune-Checkpoint Blockade Opposes CD8
Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
[TBL] [Abstract][Full Text] [Related]
37. Mature dendritic cells enriched in regulatory molecules may control regulatory T cells and the prognosis of head and neck cancer.
Minohara K; Imai M; Matoba T; Wing JB; Shime H; Odanaka M; Uraki R; Kawakita D; Toyama T; Takahashi S; Morita A; Murakami S; Ohkura N; Sakaguchi S; Iwasaki S; Yamazaki S
Cancer Sci; 2023 Apr; 114(4):1256-1269. PubMed ID: 36529525
[TBL] [Abstract][Full Text] [Related]
38. CTLA-4 blockade induces tumor pyroptosis via CD8
Wang S; Wu ZZ; Zhu SW; Wan SC; Zhang MJ; Zhang BX; Yang QC; Xiao Y; Li H; Mao L; Wang ZY; Gutkind JS; Sun ZJ
Mol Ther; 2023 Jul; 31(7):2154-2168. PubMed ID: 36869589
[TBL] [Abstract][Full Text] [Related]
39. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
40. Increased PD-1
Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
